Isosorbide

05/01/1993 - "Eighteen patients died (9 in the isosorbide-treated group), 6 due to bleeding. "
05/01/2008 - "beta-Blockers+/-isosorbide-5-mononitrate and band ligation are effective in preventing recurrent bleeding and both can be used. "
01/01/2000 - "In cirrhotic patients with acute gastro-oesophageal variceal bleeding, addition of isosorbide 5-mononitrate to somatostatin does not improve therapeutic efficacy, induces more adverse effects, and should not be used."
04/01/1997 - "Propranolol or isosorbide therapy is effective in the prophylaxis of variceal bleeding. "
01/01/2004 - "In contrast to conventional NO-donors such as isosorbide mono- and di-nitrate, which are also used for primary and secondary prevention of gastrointestinal bleeding, NCX-1000 has no effect on mean arterial pressure in either normal or cirrhotic animals indicating the absence of adverse systemic effect. "

09/01/1975 - "These data demonstrate that the objectives of therapy in congestive heart failure, namely improved forward output and decreased ventricular filling pressures, can be achieved without metabolic deterioration by using sublingual isosorbide. "
03/01/2001 - "Isosorbide 5-mononitrate (5-ISMN) was evaluated in normal dogs and dogs with congestive heart failure (CHF) in a randomized, blinded, and placebo-controlled study. "
01/01/2007 - "[Endothelial dysfunction in patients with chronic heart failure, and possibilities of its correction with isosorbide-5-mononitrates]."
01/01/1987 - "Acute and chronic use of isosorbide 5-mononitrate in patients with heart failure."
02/01/2006 - "To evaluate sublingual isosorbide administration as a test of reversibility of pulmonary hypertension in heart failure. "

06/01/1995 - "Eighteen patients with acute myocardial infarction (AMI) followed the same extended-release isosorbide 5-mononitrate dosage regimen as was used in the Fourth International Study of Infarct Survival (ISIS-4). "
02/01/1990 - "The effects of oral isosorbide 5-mononitrate on mortality following acute myocardial infarction: a multicentre study."
01/01/1987 - "Controlled study of the haemodynamic effects of isosorbide 5-mononitrate in acute myocardial infarction."
06/01/1995 - "The plasma concentrations of isosorbide 5-mononitrate (5-ISMN) administered in an extended-release form to patients with acute myocardial infarction."
07/01/1990 - "The effects of oral isosorbide 5-mononitrate on mortality following acute myocardial infarction."

11/01/1977 - "Isosorbide may be effective in a variable proportion of various types of infantile hydrocephalus. "
02/01/1992 - "Although isosorbide did extend the interval between back closure and shunt placement, its side-effects and the availability of alternative treatments render it unsuitable for the management of hydrocephalus in children with myelodysplasia."
02/01/1992 - "Fourteen children with hydrocephalus associated with myelodysplasia were given isosorbide (8 to 12 g/kg/day) and compared with 17 children managed without it. "
02/01/1992 - "Isosorbide in the medical management of hydrocephalus in children with myelodysplasia."
08/01/1983 - "Isosorbide in the management of infantile hydrocephalus."

08/01/2000 - "Isosorbide was infused continuously to prevent myocardial ischemia. "
03/01/1991 - "[Effectiveness of the delayed-action form of isosorbide 5-mononitrate in ischemic heart disease]."
01/01/1989 - "[Combination therapy with slow release isosorbide nitrate and diltiazem in silent myocardial ischemia]."
01/01/1987 - "Oral isosorbide 5-mononitrate can protect from myocardial ischemia induced by ergonovine test and by isometric effort. "
01/01/2000 - "[Comparative study of isosorbide dinitrates and mononitrates in patients with ischemic heart disease and stable angina pectoris caused by stenosing coronary atherosclerosis]."